Mirati Therapeutics Total Liabilities

Mirati Therapeutics (MRTX) currently reports a total liabilities of $180M as of September 2023. That compares with $170M in the prior-year period — up 5.3% year over year. Use the charts on this page to explore Mirati Therapeutics's total liabilities history and peer comparisons.

Mirati Therapeutics's total liabilities increased from $170M to $180M — a 5.3% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mirati Therapeutics reported $180M in total liabilities as of September 2023. That compares with $170M in the prior-year period — up 5.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $180M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Mirati Therapeutics, and consider following MRTX for alerts when major investors trade the stock.

Mirati Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $180M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRTX with unrelated industries.